Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study) - Takeaways - MDSpire

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

  • By

  • Nabil E. Omar

  • Shereen Elazzazy

  • Anas Hamad

  • Mohamed Omar Saad

  • Aya Alasmar

  • Sahar M. Nasser

  • Maria Benkhadra

  • Hebatalla M. Afifi

  • Farah I. Jibril

  • Rawan A. Dawoud

  • Mohamed S. Hamid

  • Afnan Alnajjar

  • Arwa O. Sahal

  • Amaal Gulied

  • Hazem Elewa

  • June 19, 2026

  • 0 min

Share

  • 1

    The article discusses an erratum regarding the SAFE-ICI-Q study on immune checkpoint inhibitors in cancer therapy.

  • 2

    The authors include Omar NE, Elazzazy S, Hamad A, and others, indicating a collaborative research effort.

  • 3

    The omission of a funding statement was corrected, noting support from the Qatar National Library.

  • 4

    The original publication has been updated to reflect this correction.

  • 5

    The study evaluates the safety profile of immune checkpoint inhibitors based on real-world data from Qatar.

Original Source(s)

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

  • by Nabil E. Omar, Shereen Elazzazy, Anas Hamad, Mohamed Omar Saad, Aya Alasmar, Sahar M. Nasser, Maria Benkhadra, Hebatalla M. Afifi, Farah I. Jibril, Rawan A. Dawoud, Mohamed S. Hamid, Afnan Alnajjar, Arwa O. Sahal, Amaal Gulied, Hazem Elewa

  • June 19, 2026

Related Content

Editorial: The role of immune and stromal mediators in the formation of pre-metastatic and metastatic niches: the gateway to metastasis

An IHC-derived TLS–CD8–macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC

Neural regulation of tumor progression: implications for hepatocellular carcinoma